Esperion Therapeutics, Inc. — Director's Dealing 2017

Jan 4, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2017-01-03

Reporting Person: Lalwani Narendra D. (Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-01-03	Stock Option (right to buy)	$12.88	A	55000	Acquired	2027-01-03	Common Stock (55000)	Direct

Footnotes

F1: The options vest over a four (4) year period in equal quarterly installments, the first of which will be on April 3, 2017.